Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Decoy Therapeutics Inc. (DCOY)

Decoy Therapeutics agrees to about $3.5 million private placement with milestone warrants

Negative Impact 3 of 5 financing Written later

Decoy Therapeutics entered into a securities purchase agreement on June 26, 2026 to sell 592,217 shares of common stock at $5.91 per share to one institutional investor, with closing expected on or about June 29, 2026. The deal also includes milestone-based warrants that could bring up to about $17.5 million more in gross proceeds if exercised, which would add to existing shareholder dilution and depends on future milestones and stockholder approval.

Key points

  • Expected gross proceeds of about $3.5 million before placement agent fees and offering expenses
  • 592,217 shares priced at $5.91 per share, with pre-funded warrants available to the investor in lieu of shares
  • Series A, B and C milestone warrants could add up to about $17.5 million if fully exercised after milestones and stockholder approval
  • Placement agent Curvature Securities receives a 9.0% cash fee; a resale registration statement is due within 15 calendar days of the registration rights agreement

The filing

CompanyDecoy Therapeutics Inc. (DCOY)
Form8-K, current report
Filed with the SECJun 29, 2026, 6:03 AM ET
Accession number0001193125-26-286737

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.